Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:CYTK NASDAQ:KRYS NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$22.03+0.0%$24.26$19.11▼$48.45$2.06B0.192,645 shs537 shsCYTKCytokinetics$77.09+16.7%$64.00$29.31▼$80.20$8.21B0.381.67 million shs18.07 million shsKRYSKrystal Biotech$284.57-0.8%$262.18$122.80▼$303.00$8.45B0.5260,992 shs414,552 shsPCVXVaxcyte$55.60-4.9%$58.67$28.09▼$65.00$8.45B1.31.09 million shs2.17 million shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%-0.13%-14.85%+0.04%-8.40%CYTKCytokinetics0.00%+2.84%-5.07%-2.13%+69.61%KRYSKrystal Biotech0.00%-2.46%+1.95%-4.84%+60.11%PCVXVaxcyte0.00%-4.67%-2.48%+2.15%+60.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$22.03+0.0%$24.26$19.11▼$48.45$2.06B0.192,645 shs537 shsCYTKCytokinetics$77.09+16.7%$64.00$29.31▼$80.20$8.21B0.381.67 million shs18.07 million shsKRYSKrystal Biotech$284.57-0.8%$262.18$122.80▼$303.00$8.45B0.5260,992 shs414,552 shsPCVXVaxcyte$55.60-4.9%$58.67$28.09▼$65.00$8.45B1.31.09 million shs2.17 million shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%-0.13%-14.85%+0.04%-8.40%CYTKCytokinetics0.00%+2.84%-5.07%-2.13%+69.61%KRYSKrystal Biotech0.00%-2.46%+1.95%-4.84%+60.11%PCVXVaxcyte0.00%-4.67%-2.48%+2.15%+60.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.25Buy$46.67111.83% UpsideCYTKCytokinetics 2.82Moderate Buy$92.1019.63% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.1113.92% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0054.69% UpsideCurrent Analyst Ratings BreakdownLatest AAPG, PCVX, CYTK, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026CYTKCytokinetics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$106.005/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/5/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $102.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/24/2026AAPGAscentage Pharma Group International Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/20/2026CYTKCytokinetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.004/10/2026CYTKCytokinetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$95.004/9/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/8/2026PCVXVaxcyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$82.10M25.04N/AN/A$2.04 per share10.80CYTKCytokinetics$88.04M108.64N/AN/A($5.39) per share-14.28KRYSKrystal Biotech$389.13M21.52$7.79 per share36.50$42.06 per share6.76PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics-$784.96M-$6.53N/AN/AN/A-891.60%N/A-49.62%5/5/2026 (Estimated)KRYSKrystal Biotech$204.83M$6.8541.5425.89N/A52.64%18.69%17.12%N/APCVXVaxcyte-$766.63M-$5.62N/AN/AN/AN/A-25.88%-23.85%5/6/2026 (Estimated)Latest AAPG, PCVX, CYTK, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026PCVXVaxcyte-$1.7411N/AN/AN/A$12.50 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67N/AN/AN/A$8.52 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/25/2026Q4 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 million2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77CYTKCytokineticsN/A4.534.53KRYSKrystal BiotechN/A9.959.56PCVXVaxcyteN/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACYTKCytokineticsN/AKRYSKrystal Biotech86.29%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACYTKCytokinetics2.60%KRYSKrystal Biotech13.10%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.33 millionN/AN/ACYTKCytokinetics250124.24 million121.01 millionOptionableKRYSKrystal Biotech21029.44 million25.58 millionOptionablePCVXVaxcyte160144.39 million139.91 millionOptionableAAPG, PCVX, CYTK, and KRYS HeadlinesRecent News About These CompaniesVaxcyte (NASDAQ:PCVX) Stock Price Down 6.8% - What's Next?3 hours ago | marketbeat.comVanguard Group Inc. Sells 126,467 Shares of Vaxcyte, Inc. $PCVXMay 5 at 8:19 AM | marketbeat.comJennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVXMay 2 at 6:48 AM | marketbeat.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV MarketMay 1, 2026 | seekingalpha.comVaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in StockMay 1, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVXMay 1, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Cut to "Strong Sell" at Wall Street ZenMay 1, 2026 | americanbankingnews.comPictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVXApril 30, 2026 | marketbeat.comVaxcyte (PCVX) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Rating Lowered to Strong Sell at Wall Street ZenApril 28, 2026 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.com5 Best 52-Week High US Stocks to BuyApril 23, 2026 | insidermonkey.comVaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageApril 23, 2026 | insidermonkey.comVaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street ZenApril 20, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Rating Lowered by Wall Street ZenApril 12, 2026 | marketbeat.comIs It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?April 11, 2026 | finance.yahoo.comElvia Cowan Sells 3,000 Shares of Vaxcyte (NASDAQ:PCVX) StockApril 9, 2026 | insidertrades.comInsider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells 3,000 Shares of StockApril 8, 2026 | marketbeat.comVaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comAberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVXApril 5, 2026 | marketbeat.comVaxcyte joins elite club of stocks with RS ratings over 90March 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAPG, PCVX, CYTK, and KRYS Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$22.03 +0.01 (+0.05%) Closing price 03:59 PM EasternExtended Trading$22.08 +0.05 (+0.23%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Cytokinetics NASDAQ:CYTK$77.09 +11.04 (+16.71%) Closing price 04:00 PM EasternExtended Trading$76.81 -0.28 (-0.36%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$284.57 -2.38 (-0.83%) Closing price 04:00 PM EasternExtended Trading$284.51 -0.06 (-0.02%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Vaxcyte NASDAQ:PCVX$55.60 -2.89 (-4.95%) Closing price 03:59 PM EasternExtended Trading$55.52 -0.08 (-0.15%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
